

18-04162-E

**RECEIVED**

APR 27 2018

Office of  
FOIA Services

April 26, 2018

Dear SEC FOIA Office:

*I am requesting a copy of  
Exhibit 10.2 to Form 10-Q filed by Juno Therapeutics, Inc. on 08/14/2015.  
I am willing to pay up to \$61.00.*

*Thank you,*

*Diane Martin*

**AUS Consultants Inc.**  
155 Gaither Dr, Suite A  
Mt. Laurel  
NJ 08054  
856.234.9200



UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
STATION PLACE  
100 F STREET, NE  
WASHINGTON, DC 20549-2465

Office of FOIA Services

May 1, 2018

Ms. Diane Martin  
AUS Consultants, Inc.  
155 Gaither Dr., Suite A  
Mt. Laurel, NJ 08054

RE: Freedom of Information Act (FOIA), 5 U.S.C. § 552  
Request No. 18-04162-E

Dear Ms. Martin:

This letter is in response to your request, dated April 26, 2018 and received in this office on April 27, 2018, for Exhibit 10.2 to Form 10-Q filed by Juno Therapeutics, Inc. on August 14, 2015.

The Commission granted confidential treatment (CT) to Exhibit 10.2 to the Form 10-Q under Rule 24b-2 of the Securities Exchange Act of 1934 through October 13, 2018. Since confidential treatment has not expired, we are providing you with a copy of the relevant CT order.

If you have any questions, please contact me at [jacksonw@sec.gov](mailto:jacksonw@sec.gov) or (202) 551-8312. You may also contact me at [foiapa@sec.gov](mailto:foiapa@sec.gov) or (202) 551-7900. You also have the right to seek assistance from a FOIA Public Liaison, Jeffery Ovall at (202) 551-7900.

Sincerely,

A handwritten signature in black ink that reads "Warren E. Jackson".

Warren E. Jackson  
FOIA Research Specialist

Enclosure

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
February 8, 2016**

**ORDER GRANTING CONFIDENTIAL TREATMENT  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**Juno Therapeutics, Inc.**

**File No. 1-36781 - CF#32902**

---

Juno Therapeutics, Inc. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the exhibits to a Form 10-Q filed on August 14, 2015, as amended.

Based on representations by Juno Therapeutics, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:

Exhibit 10.1	through	October 13, 2018
<b>Exhibit 10.2</b>	<b>through</b>	<b>October 13, 2018</b>
Exhibit 10.7	through	October 13, 2018
Exhibit 10.12	through	December 12, 2018

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields  
Secretary